CA2146607A1 - Composition pharmaceutique pour le traitement des maladies proliferatives de l'epiderme - Google Patents

Composition pharmaceutique pour le traitement des maladies proliferatives de l'epiderme

Info

Publication number: CA2146607A1
Authority: CA; Canada
Prior art keywords: pharmaceutical composition; epidermis; treatment; pharmacologically acceptable; acceptable salt
Prior art date: 1994-04-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002146607A

Other languages

English (en)

Inventor

Kazumi Ogata

Takahiro Sakaue

Sachiko Matsuura

Rie Nagao

Shinya Ogino

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Senju Pharmaceutical Co Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-22

Filing date

1995-04-07

Publication date

1995-10-23

1995-04-07 Application filed by Individual filed Critical Individual

1995-10-23 Publication of CA2146607A1 publication Critical patent/CA2146607A1/fr

Status Abandoned legal-status Critical Current

Links

210000002615 epidermis Anatomy 0.000 title claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
201000010099 disease Diseases 0.000 title claims abstract description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
230000002062 proliferating effect Effects 0.000 title claims abstract description 14
150000003839 salts Chemical class 0.000 claims abstract description 15
-1 diester compound Chemical class 0.000 claims abstract description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 21
239000007788 liquid Substances 0.000 claims description 9
239000002674 ointment Substances 0.000 claims description 9
230000000699 topical effect Effects 0.000 claims description 6
238000000034 method Methods 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 abstract description 12
239000000203 mixture Substances 0.000 abstract description 10
229940126585 therapeutic drug Drugs 0.000 abstract description 3
206010033554 Palmoplantar keratoderma Diseases 0.000 abstract description 2
206010021198 ichthyosis Diseases 0.000 abstract description 2
201000008743 palmoplantar keratosis Diseases 0.000 abstract description 2
206010035116 pityriasis rubra pilaris Diseases 0.000 abstract description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
239000003814 drug Substances 0.000 description 10
VIHIKSJKXIMMLV-FZTHFCCHSA-M potassium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate Chemical compound [K+].C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP([O-])(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O VIHIKSJKXIMMLV-FZTHFCCHSA-M 0.000 description 10
229940079593 drug Drugs 0.000 description 8
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
239000000499 gel Substances 0.000 description 7
230000000694 effects Effects 0.000 description 5
238000010172 mouse model Methods 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229960004311 betamethasone valerate Drugs 0.000 description 4
SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000004584 weight gain Effects 0.000 description 4
235000019786 weight gain Nutrition 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229940124599 anti-inflammatory drug Drugs 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
241000894007 species Species 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
206010015150 Erythema Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229940043274 prophylactic drug Drugs 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010014025 Ear swelling Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010027304 Menopausal symptoms Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
IOZWJJBOYMUHEJ-HMQIKIGCSA-N [(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] hydrogen phosphate Chemical class C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP(O)(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O IOZWJJBOYMUHEJ-HMQIKIGCSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
230000001437 anti-cataract Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940115445 ascorbyl tocopheryl phosphate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000008406 cosmetic ingredient Substances 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000008311 hydrophilic ointment Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000009103 reabsorption Effects 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
238000012827 research and development Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Mobile Radio Communication Systems (AREA)

CA002146607A 1994-04-22 1995-04-07 Composition pharmaceutique pour le traitement des maladies proliferatives de l'epiderme Abandoned CA2146607A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP6-84246		1994-04-22
JP6084246A JPH07298351A (ja)	1994-04-22	1994-04-22	携帯電話システム

Publications (1)

Publication Number	Publication Date
CA2146607A1 true CA2146607A1 (fr)	1995-10-23

Family

ID=13825111

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002146607A Abandoned CA2146607A1 (fr)	1994-04-22	1995-04-07	Composition pharmaceutique pour le traitement des maladies proliferatives de l'epiderme

Country Status (2)

Country	Link
JP (1)	JPH07298351A (fr)
CA (1)	CA2146607A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU716427B2 (en) *	1996-03-22	2000-02-24	Kyocera Corporation	Communication system of portable communication terminal, incoming call control system of portable communication terminal and incoming call notifying device of portable communication terminal
JP3034128U (ja) *	1996-03-26	1997-02-14	京セラ株式会社	携帯電話の着信通知システム
JP3034129U (ja) *	1996-03-26	1997-02-14	京セラ株式会社	携帯電話の着信通知システム
JP3034127U (ja) *	1996-03-28	1997-02-14	京セラ株式会社	携帯電話の着信通知システム

1994
- 1994-04-22 JP JP6084246A patent/JPH07298351A/ja not_active Withdrawn
1995
- 1995-04-07 CA CA002146607A patent/CA2146607A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
JPH07298351A (ja)	1995-11-10

Legal Events

Date	Code	Title	Description
2003-04-07	FZDE	Discontinued

Publication	Publication Date	Title
US10881640B2 (en)	2021-01-05	Topical pharmaceutical compositions for treatment of pilonidal sinus wounds
AU2004233587B2 (en)	2008-02-07	Use of a topical medicament comprising Riluzole
US20060222671A1 (en)	2006-10-05	Dermatological compositions and salts for the treatment of dermatological diseases
EP0679399B1 (fr)	1997-08-06	L'utilisation des diesters phosphatiques pour le traitement des maladies prolifératives de l'épiderme
EP2035006B1 (fr)	2010-02-17	Utilisation d'allopurinol pour le traitement de l'érythrodysesthésie palmaire et plantaire
WO2002036592A1 (fr)	2002-05-10	Remedes aux maladies causees par l'acide arachidonique
EP1559426B1 (fr)	2011-02-09	Preparations d'absorption percutanee contenant du 3-methyl-1-phenyl-2-pyrazolin-5-one
US6093745A (en)	2000-07-25	Methods and composition for treating skin proliferative diseases
CA2146607A1 (fr)	1995-10-23	Composition pharmaceutique pour le traitement des maladies proliferatives de l'epiderme
EP0680760A1 (fr)	1995-11-08	Composition antipruritique topique contenant un diester de l'acide phosphorique
JPH083049A (ja)	1996-01-09	表皮増殖疾患治療剤
US5556871A (en)	1996-09-17	Method for treating epithelial precancerous lesions with topical inidazoles
KR20080011280A (ko)	2008-02-01	피부과학적 질병의 치료를 위한 피부과학적 조성물 및 염
JPS6327432A (ja)	1988-02-05	高増殖性上皮疾患の治療のための局部的なメトトレキセ−ト調製物およびそれを用いた高増殖性上皮疾患の治療方法
JPH1180031A (ja)	1999-03-23	外用剤及び経皮又は経粘膜吸収性を増進する方法
US20030125307A1 (en)	2003-07-03	Remedies for external use for allergic skin diseases
US20200046703A1 (en)	2020-02-13	Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
US20040023937A1 (en)	2004-02-05	Anti-cancer formulation
JP2001163783A (ja)	2001-06-19	皮膚疾患治療用外用剤
JPH1095733A (ja)	1998-04-14	にきび治療薬
Lebrun-Vignes et al.	1998	Effect of itraconazole on the pharmacokinétics of prednisolone and methylprednisolone in healthy subjects
CA2575842A1 (fr)	2006-02-23	Composition contenant un derive de la thio-uree destinee a prevenir ou a traiter des maladies de la peau prurigineuses ou irritantes
AU2008200878A1 (en)	2008-03-13	Use of a topical medicament comprising riluzole
KR20020035131A (ko)	2002-05-09	덱스라족산의 건선 치료 용도
Al-Timimi et al.	2007	Doxycycline in pityriasis rosea: placebo-controlled clinical trial